Xian Yihang Technology
Retatrutide
Finnrick tested 8 samples of Retatrutide (GLP-1, GIP, and GCGR agonist) from Xian Yihang Technology between 27 Jun 2025 and 23 Oct 2025. Test scores average over 4, no score below 3, and at least 6 tests warrant a confident Finnrick Rating of D (Poor).
Finnrick Rating™
Xian Yihang Technology
Retatrutide
Tested 8 Samples
Last test 23 Oct 2025
Take Action
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Retatrutide tests from top-rated vendors:
All Retatrutide tests from Xian Yihang Technology
Samples are tested in commercial labs
Tests Count
8
Scores
AVGMINMAX
Last
23 Oct 2025
First
27 Jun 2025
| Quantity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 23 Oct 2025 | View | 5mg | 4.590mg | -8.2% | 99.29% | (no batch ID) | (no data) | Lab E | Public | |
| 23 Oct 2025 | View | 5mg | 4.370mg | -12.6% | 99.43% | (no batch ID) | No Label / Silver Crimp / Yellow Cap | Lab E | Public | |
| 13 Oct 2025 | View | 10mg | 11.700mg | +17.0% | 99.70% | (no batch ID) | No Label / Silver Crimp / Green Cap | Lab G | Public | |
| 7 Oct 2025 | View | 5mg | 5.800mg | +16.0% | 99.00% | (no batch ID) | (no data) | Lab G | Public | |
| 10 Sep 2025 | View | 10mg | 8.500mg | -15.0% | 99.95% | (no batch ID) | White Label / Silver Crimp / Black Cap | Lab E | Public | |
| 4 Aug 2025 | View | 10mg | 11.780mg | +17.8% | 99.20% | rt100520 | No Label / Silver Crimp / Green Cap | Lab D | Public | |
| 3 Jul 2025 | View | 10mg | 9.940mg | -0.6% | 99.58% | (no batch ID) | No Label / Silver Crimp / Clear Blue Cap | Lab E | Public | |
| 27 Jun 2025 | View | 10mg | 11.290mg | +12.9% | 99.97% | rt100520 | No Label / Silver Crimp / Green Cap | Lab A | Public | |